Integrase inhibitor

Integrase inhibitors are a type of antiretroviral medication used in the treatment and prevention of HIV/AIDS. They work by inhibiting the action of integrase, an enzyme produced by the HIV virus that enables it to replicate within the host's cells.

Mechanism of Action[edit | edit source]

Integrase is an enzyme that allows the HIV virus to integrate its genetic material into the DNA of the host cell. This integration is a crucial step in the viral lifecycle, as it allows the virus to replicate and spread throughout the body. Integrase inhibitors work by binding to the integrase enzyme and preventing it from performing this function. This effectively halts the replication of the virus and slows the progression of the disease.

Types of Integrase Inhibitors[edit | edit source]

There are several types of integrase inhibitors, including:

Raltegravir - The first integrase inhibitor to be approved by the FDA, in 2007.
Elvitegravir - Approved by the FDA in 2012, it is often used in combination with other antiretroviral medications.
Dolutegravir - This drug was approved by the FDA in 2013 and has been shown to be effective in patients who have developed resistance to other antiretroviral medications.
Bictegravir - Approved by the FDA in 2018, it is used in combination with other antiretroviral medications.

Side Effects and Risks[edit | edit source]

Like all medications, integrase inhibitors can have side effects. These can include nausea, diarrhea, and headache. In rare cases, they can cause severe skin reactions and liver problems. It's important for patients to discuss these risks with their healthcare provider before starting treatment.

Future Research[edit | edit source]

Research is ongoing to develop new integrase inhibitors and to improve the effectiveness and safety of existing ones. This includes studies to understand the mechanisms of resistance to integrase inhibitors and to develop strategies to overcome this resistance.